Comparing the current results to its competitors, Corbus Pharmaceuticals Holdings Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 26.73 %, recorded in the same quarter.
Corbus Pharmaceuticals Holdings Inc , slower than the average decrease reported by the company's competitors of -34.94 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -34.94 %
Corbus Pharmaceuticals Holdings Inc 's Comment on Competition and Industry Peers
The company competes with major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and public and private research organizations. Competitors to CRB-701, which involves antibody-drug conjugates (ADCs) targeting Nectin-4 with MMAE, include Bicycle Therapeutics plc, Mabwell, and Pfizer Inc., the latter with its approved product PADCEV®. Additional competitors targeting similar indications through different mechanisms include Bicara Therapeutics, Inc., Genmab A/S, Johnson and Johnson, and Pfizer Inc. Competitors to CRB-913, which targets the CB-1 receptor, include Novo Nordisk A/S and Skye Bioscience. Other companies developing oral drugs for weight loss competition include AstraZeneca PLC, Lilly, Novo Nordisk A/S, Structure Therapeutics Inc., and Viking Therapeutics, Inc.
October 16, 2024
Corbus Pharmaceuticals Advances in Oncology with CRB-701 NORWOOD, Mass. Oct. 16, 2024 In a significant milestone for cancer therapeutics, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has completed enrollment for the dose escalation stage of its Phase 1 clinical trial for CRB-701 (SYS6002), an innovative Nectin-4 targeting antibody-drug conjugate (ADC). This advancement marks a pivotal step in the journey toward addressing the unmet medical needs associated with advanced solid tumors driven by high expression of Nectin-4.The open-label study, currently underway in both the United States and the United Kingdom, is designed to evaluate not only the safety and pharmacokinetics of CRB-701 but also its...
January 9, 2024
In the field of cancer therapeutics, precision oncology approaches have gained significant attention due to their promise in delivering personalized treatments with improved efficacy. Corbus Pharmaceuticals Holdings, Inc. has achieved a major milestone with the clearance of the investigational new drug application of CRB-601 by the U.S. Food and Drug Administration (FDA). CRB-601 is a novel monoclonal antibody that targets the integrin v8 and exhibits potential as a best-in-class TGF blocking agent. The groundbreaking pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrated the ability of CRB-601 to overcome tumor immune exclusion and enhance the a...
Publicly Traded Peers of Corbus Pharmaceuticals Holdings Inc
Evoke Pharma Inc Share Performance
+146.09%
This Year
Evoke Pharma Inc
Profile
Evoke Pharma Inc operates as a specialty pharmaceutical company focusing on the development and commercialization of drugs for the treatment of gastrointestinal disorders. Their business model involves researching, developing, and marketing innovative pharmaceutical products to address unmet medical needs in the gastrointestinal market.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.
Sources:
Corbus Pharmaceuticals Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Corbus Pharmaceuticals Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
